HOSPIRA ANNOUNCES SUCCESSFUL COMPLETION OF TENDER OFFER FOR SHARES OF
LAKE FOREST, Ill., July 1, 2010 — Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and
medication delivery company, today announced the successful completion of the tender offer by Discus
Acquisition Corporation, a wholly owned Hospira subsidiary, to purchase all outstanding shares of the common
stock of Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV).
As previously announced, the offer expired at 12:00 midnight, New York City time, on June 30, 2010 (the end
of the day on June 30, 2010). Based on information provided by Computershare Trust Company, N.A., the
depositary for the offer, as of the close of business on the expiration date of the offer, 51,346,299 Javelin shares
were validly tendered and not withdrawn. The tendered shares represent approximately 79.16% of Javelin’s
outstanding shares of common stock. All Javelin shares that were validly tendered and not withdrawn immediately
prior to the expiration of the offer have been accepted by Hospira for payment. Hospira will purchase and pay
for all such shares promptly.
In accordance with the merger agreement among the parties, Hospira intends to exercise its “top-up” option to
increase its share ownership percentage of Javelin shares through the purchase from Javelin of newly issued
shares of Javelin common stock at the same $2.20 per share paid in the tender offer in order to allow Hospira to
effect a short-term merger under Delaware law.
Hospira intends to promptly complete the acquisition of Javelin through a short-form merger under Delaware law,
as soon as practicable, with the completion of the merger anticipated to occur on or about July 2, 2010. As a
result of the merger, any remaining shares of Javelin common stock will be converted into the right to receive the
offer price of $2.20 in cash paid in the tender offer, without interest and less any required withholding taxes (oth